EFM
AKBA icon

E Fund Management’s Akebia Therapeutics AKBA Stock Holding History

E Fund Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,119
Closed -$57.2K – 491
2026
Q1 		$57.2K Buy
+41,119
New +$56.5K ﹤0.01% 486
2025
Q2 		$103K Buy
28,273
+8,962
+46% +$24.6K ﹤0.01% 375
2025
Q1 		$37.1K Buy
19,311
+6,595
+52% +$13.5K ﹤0.01% 395
2024
Q4 		$24.2K Buy
+12,716
New +$22.1K ﹤0.01% 394
2022
Q2 		– Sell
-35,250
Closed -$25K – 324
2022
Q1 		$25K Buy
35,250
+10,853
+44% +$23.2K ﹤0.01% 325
2021
Q4 		$55K Sell
24,397
-12,726
-34% -$34.7K ﹤0.01% 296
2021
Q3 		$107K Buy
+37,123
New +$106K ﹤0.01% 258
2021
Q1 		$130K Buy
+38,410
New +$138K 0.01% 229

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

E Fund Management's AKBA Position: Q2 2026 in Review

E Fund Management sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 41,119 shares — an estimated $57.2K sold.

E Fund Management first reported a position in AKBA in Q1 2021 and held it in 8 quarters. The position peaked at $130K in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • E Fund Management reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • E Fund Management sold 41,119 Akebia Therapeutics shares in Q2 2026, an estimated $57.2K.
  • E Fund Management first reported a position in Akebia Therapeutics in Q1 2021 and held it in 8 quarters.
  • E Fund Management's Akebia Therapeutics position peaked at $130K in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.